Structure via PubChem · Public domain (PubChem)
etelcalcetide
Sign in to saveAlso known as Velcalcetide
Etelcalcetide, sold under the brand name Parsabiv, is a calcimimetic medication for the treatment of secondary hyperparathyroidism in people undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Chemical data
- Formula
- C38H73N21O10S2
- Molecular weight
- 1048.3 g/mol
- IUPAC name
- (2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid
- SMILES
- C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C
- InChIKey
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N
- XLogP
- -10.7
- Polar surface area
- 618 Ų
- H-bond donors
- 18
- H-bond acceptors
- 17
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2016
- Admin. routes
- parenteral
- Indications
- secondary hyperparathyroidism, chronic kidney disease, parathyroid disease
via ChEMBL · EBI
Wikidata facts
- Mass
- 1047.529
- Has use
- medication
Show 7 more facts
- medical condition treated
- secondary hyperparathyroidism
- canonical SMILES
- CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C
- chemical formula
- C₃₈H₇₃N₂₁O₁₀S₂
- isomeric SMILES
- C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O
- NCI Thesaurus ID
- C129712
- defined daily dose
- 2.1
- physically interacts with
- calcium sensing receptor
Sources (3)
via Wikidata · CC0
~3 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Pharmacodynamics
- Mechanism of action
- Pharmacokinetics
- Side effects
- Contraindications
- Chemistry
- History
- Research
- References
Etelcalcetide, sold under the brand name Parsabiv, is a calcimimetic medication for the treatment of secondary hyperparathyroidism in people undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
==Medical uses== Etelcalcetide is used for the treatment of secondary hyperparathyroidism in people with chronic kidney disease (CKD) on hemodialysis. Hyperparathyroidism is the condition of elevated parathyroid hormone (PTH) levels and is often observed in people with CKD.
Excerpted from Wikipedia’s “etelcalcetide” article, available under the CC BY-SA 4.0 licence.